Anti-inflammatory and anticancer activities of Naringenin-loaded liquid crystalline nanoparticles in vitro

  • Ridhima Wadhwa
  • , Keshav Raj Paudel
  • , Li Hian Chin
  • , Chian Ming Hon
  • , Thiagarajan Madheswaran
  • , Gaurav Gupta
  • , Jithendra Panneerselvam
  • , Thangavelu Lakshmi
  • , Sachin Kumar Singh
  • , Monica Gulati
  • , Harish Dureja
  • , Alan Hsu
  • , Meenu Mehta
  • , Krishnan Anand
  • , Hari Prasad Devkota
  • , Jestin Chellian
  • , Dinesh Kumar Chellappan
  • , Philip M. Hansbro
  • , Kamal Dua

Research output: Contribution to journalArticlepeer-review

117 Citations (Scopus)

Abstract

In this study, we had developed Naringenin-loaded liquid crystalline nanoparticles (LCNs) and investigated the anti-inflammatory and anticancer activities of Naringenin-LCNs against human airway epithelium-derived basal cells (BCi-NS1.1) and human lung epithelial carcinoma (A549) cell lines, respectively. The anti-inflammatory potential of Naringenin-LCNs evaluated by qPCR revealed a decreased expression of IL-6, IL-8, IL-1β, and TNF-α in lipopolysaccharide-induced BCi-NS1.1 cells. The activity of LCNs was comparable to the positive control drug Fluticasone propionate (10 nM). The anticancer activity was studied by evaluating the antiproliferative (MTT and trypan blue assays), antimigratory (scratch wound healing assay, modified Boyden chamber assay, and immunoblot), and anticolony formation activity in A549 cells. Naringenin LCNs showed promising antiproliferative, antimigratory, and anticolony formation activities in A549 cells, in vitro. Therefore, based on our observations and results, we conclude that Naringenin-LCNs may be employed as a potential therapy-based intervention to ameliorate airway inflammation and to inhibit the progression of lung cancer. Practical applications: Naringenin was encapsulated into liquid crystalline nanoparticles, thus, attributing to their sustained-release nature. In addition, Naringenin-loaded LCNs efficiently reduced the levels of pro-inflammatory markers, namely, IL-1β, IL-6, TNF-α, and IL-8. In addition, the Naringenin-loaded LCNs also possess potent anticancer activity, when tested in the A549 cell line, as revealed by the inhibition of proliferation and migration of cells. They also attenuated colony formation and induced apoptosis in the A549 cells. The findings from our study could form the basis for future research that may be translated into an in vivo model to validate the possible therapeutic alternative for lung cancer using Naringenin-loaded LCNs. In addition, the applications of Naringenin-loaded LCNs as an intervention would be of great interest to biological, formulation and respiratory scientists and clinicians.

Original languageEnglish
Article numbere13572
JournalJournal of Food Biochemistry
Volume45
Issue number1
DOIs
Publication statusPublished - Jan 2021
Externally publishedYes

Bibliographical note

Publisher Copyright:
© 2020 Wiley Periodicals LLC.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • anti-inflammatory
  • liquid crystalline nanoparticles
  • lung cancer
  • migration
  • Naringenin
  • proliferation

Fingerprint

Dive into the research topics of 'Anti-inflammatory and anticancer activities of Naringenin-loaded liquid crystalline nanoparticles in vitro'. Together they form a unique fingerprint.

Cite this